By the beginning of 2013, the biotech industry buzzed with several new and innovative drug-delivery devices recently on the market or well on their way to approval.
FierceDrugDelivery is taking a closer look at some of these novel devices. Each offers an example of where the industry is headed this year. And many of them center around patient compliance, as some of the biggest names in the business are turning to patient-friendly designs and expanded treatment options to make their devices more marketable.
From "talking" epinephrine injectors to long-lasting birth control devices already on the market and a recently approved next-gen glucose monitor combined with an insulin pump, some of the devices on our list have begun making waves already. Others, like a much-discussed dissolving stent and a nonsurgical sinus implant, are still in clinical trials but show promise in an increasingly patient-friendly arena. By combining innovative design with tried-and-true delivery methods, these devices allow for more effective and long-lasting drug regimens when compared with previous treatments, a trend that cuts to the core of the drug delivery industry.
For instance, the Auvi-Q from Sanofi ($SNY) helps patients and caretakers feel more comfortable giving (and receiving) an emergency injection of epinephrine, simply by providing verbal recorded instructions. Others, like Intersect ENT's sinusitis implant, Bayer's Skyla IUD and Abbott's ($ABT) Absorb dissolving stent offer increased longevity and fewer surgical complications than previous incarnations of the devices. And Insulet's next-gen Omnipod combines an insulin pump with a glucose monitoring device to deliver insulin in a new way.
Let us know what you think--what other drug-delivery device combos exist that point to a more patient-friendly 2013? -- Michael Gibney (email | Twitter)